BioPharmSignal logoBioPharmSignal

Company Sector

Immunotherapy

Immunotherapy includes companies using the immune system to fight disease, especially cancer and autoimmune conditions. This can include checkpoint inhibitors, immune agonists, engineered immune cells, therapeutic vaccines, and other approaches that modify immune activity.

Why watch Immunotherapy

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Immunotherapy news

The latest feed items from companies currently grouped under Immunotherapy.

  1. 01

    TCMDTactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

    Source: Tactile Systems Technology, Inc.

  2. 02

    BMYU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

    Source: BMYBristol-Myers Squibb Company

  3. 03

    MRKFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

    Source: Merck

  4. 04

    MRKFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Merck.com

    Source: Merck

  5. 05

    MRKMerck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Merck.com

    Source: Merck

  6. 06

    MRKMerck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Merck.com

    Source: Merck

  7. 07

    MRKGilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com

    Source: Merck

  8. 08

    MRKFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) - Merck.com

    Source: Merck

  9. 09

    MRKU.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease - Merck.com

    Source: Merck

  10. 10

    MRKMerck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Merck.com

    Source: Merck

  11. 11

    MRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer - Merck.com

    Source: Merck

  12. 12

    NEXINexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes | NexImmune, Inc.

    Source: NexImmune

  13. 13

    NEXINexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.

    Source: NexImmune

  14. 14

    NEXINexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.

    Source: NexImmune

  15. 15

    LCTXLineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

    Source: Lineage Cell Therapeutics

  16. 16

    MESOReceives FDA BLA Filing Number and Requests Modular Review

    Source: Mesoblast

  17. 17

    PSTVPlus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

    Source: PLUS THERAPEUTICS, Inc.

  18. 18

    MESOBecoming a substantial holder

    Source: Mesoblast

  19. 19

    MESOCeasing to be a substantial holder

    Source: Mesoblast

  20. 20

    LYELLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

    Source: Lyell Immunopharma

View all latest news

Companies in Immunotherapy

70 companies tagged with Immunotherapy.

ABBV

AbbVie Inc

ACIU

AC Immune

ADAP

Adaptimmune Therapeutics plc

ACET

Adicet Bio

AIM

AIM ImmunoTech

ALLO

Allogene Therapeutics

ALPN

Alpine Immune Sciences

ALT

Altimmune

AMGN

Amgen Inc.

ANAB

AnaptysBio, Inc.

ARGS

Argos

BCEL

Atreca

Frequently Asked Questions

What does the Immunotherapy sector include?

Immunotherapy includes companies using the immune system to fight disease, especially cancer and autoimmune conditions. This can include checkpoint inhibitors, immune agonists, engineered immune cells, therapeutic vaccines, and other approaches that modify immune activity.

How many companies are currently tagged with Immunotherapy?

70 companies are currently grouped under Immunotherapy on BioPharmSignal.

Which companies are most visible in the Immunotherapy group right now?

ABBV, ACIU, ADAP, ACET are among the companies currently shown on this sector page.

How can I watch news for Immunotherapy?

Use the Watch button on this page to subscribe to Immunotherapy headlines and related company updates through your BioPharmSignal saved filters.

What kinds of updates usually appear for Immunotherapy?

The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in Immunotherapy.